

ProteoTech Awarded \$770,675 U.S. Government Grant from the National Institute of Health for “Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors” for Potential Therapeutics for Alzheimer’s disease

Kirkland, WA, June 15, 2011 - ProteoTech, Inc., one of the world’s leaders in developing therapeutics and diagnostics for amyloid diseases such as Parkinson’s disease, Alzheimer’s disease and Systemic Amyloidosis, announced today that it has been awarded a Phase 1 Small Business Innovation Research Grant (SBIR) totaling approximately \$770,675 for ongoing development of its small molecule tau protein aggregation inhibitors associated with Alzheimer’s disease.

This is ProteoTech’s thirteenth SBIR award from the National Institute of Health (NIH) that it has received in the past eleven years. Since March 2000, ProteoTech has been the recipient of over \$11 million in NIH scientific peer reviewed grant awards which is an indication of the quality of its technologies and the relevance of its research to address unmet medical needs.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. The Company is developing *Synucleire*[™] for the treatment of Parkinson's disease, EXEBRYL-1[®] for the treatment of Alzheimer's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called **PeptiClere**[™] for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com